Cited by 477Atherosclerosis and Cardiovascular DiseasesCardiac Fibrosis and RemodelingBiomarkers in Disease Mechanisms

Inflammatory processes in cardiovascular disease: a route to targeted therapies

Open access
Ruparelia, Neil, Chai, Joshua T., Fisher, Edward A., Choudhury, Robin P.·2017·Nature Reviews Cardiology

Abstract

Inflammatory processes are firmly established as central to the development and complications of cardiovascular diseases. Elevated levels of inflammatory markers have been shown to be predictive of future cardiovascular events. The specific targeting of these processes in experimental models has been shown to attenuate myocardial and arterial injury, reduce disease progression, and promote healing. However, the translation of these observations and the demonstration of clear efficacy in clinical practice have been disappointing. A major limitation might be that tools currently used to measure 'inflammation' are insufficiently precise and do not provide information about disease site and activity, or discriminate between functionally important activation pathways. The challenge, therefore, is to make measures of inflammation that are more meaningful, and which can guide specific targeted therapies. In this Review, we consider the roles of inflammatory processes in the related pathologies of atherosclerosis and acute myocardial infarction, by providing an evaluation of the known and emerging inflammatory pathways. We highlight contemporary techniques to characterize and quantify inflammation, and consider how they might be used to guide specific treatments. Finally, we discuss emerging opportunities in the field, including their current limitations and challenges that are the focus of ongoing study.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrcardio.2016.185

Cites

214 of 214 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Inflammageing is a risk factor for cardiovascular disease.

    “Inflammageing is a risk factor for cardiovascular diseases (CVDs), and clinical trials suggest that this association is causal.”
  • Inflammageing is a risk factor for chronic kidney disease, diabetes mellitus, cancer, depression, dementia, and sarcopenia.

    “Inflammageing is also a risk factor for chronic kidney disease, diabetes mellitus, cancer, depression, dementia, and sarcopenia, but whether modulating inflammation beneficially affects the clinical course of non-CVD health problems is controversial.”
  • Epidemiological studies have found inflammageing is a risk factor for CVD, cancer, chronic kidney disease, dementia, depression, multimorbidity, mobility disability, ADL disability, sarcopenia, frailty, and premature death.

    “Epidemiological studies have found that inflammageing is a risk factor for CVD, cancer, chronic kidney disease, dementia, and depression as well for global indicators of poor health status, such as multimorbidity, mobility disability and disability in activities of daily living, sarcopenia, frailty, and premature death9–19.”
  • Innate and adaptive immune activation drives atherogenesis from early endothelial dysfunction to acute thrombotic complications.

    “Activation of both innate and adaptive immunity actively contributes to the initiation and progression of atherogenesis, from early endothelial dysfunction to the development of acute thrombotic complications”
  • Increased numbers of leukocytes and monocytes assessed once in the morning following 2 days of continuous wakefulness in healthy young men normalized after a single night of recovery sleep compared with control sleepers.

    “increased numbers of leukocytes and monocytes assessed once in the morning following 2 days of continuous wakefulness in healthy young men normalized after a single night of recovery sleep compared with control sleepers”

    From The Sleep-Immune Crosstalk in Health and Disease (2019) · cites this paper as [480]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ruparelia, N., Chai, J. T., Fisher, E. A., & Choudhury, R. P.
Affiliations
John Radcliffe Hospital (GB)
Corresponding author
Choudhury, Robin P.
Venue
Nature Reviews Cardiology
Published
2016-12-01
Volume
14
Issue
3
Pages
133-144
ISSN
  • 1759-5002 (ISSN-L)
  • 1759-5010
OpenAlex
W4320301265
Cited by
477
References
214
Citations by year
2026: 19 · 2025: 41 · 2024: 55 · 2023: 61 · 2022: 83 · 2021: 61 · 2020: 63 · 2019: 47 · 2018: 28 · 2017: 19
FWCI
3.02
Type
journal article
Language
en
Update notices
erratum (2017-03-16)
Open access
Locations
  • Nature Reviews Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • British Heart Foundation (PG/12/46/29673)
  • Novo Nordisk Fonden (NNF15SA0018486)
  • Medical Research Council (MR/K00266X/1)
  • National Heart, Lung, and Blood Institute (R01HL084312, P01HL092969, R01HL129433)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
  • Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
Keywords
inflammation, atherosclerosis, acute myocardial infarction, inflammatory signaling, inflammatory markers, inflammation quantification, targeted therapy, cardiovascular disease
MeSH terms
Humans, Inflammation, Myocardial Infarction, Biomarkers, Atherosclerosis, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review